TCW Group’s Charles River Laboratories CRL Stock Holding History

TCW Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3M	Buy	13,230 +1,877	+17%	+$334K	0.02%	253
2026 Q1	$1.96M	Buy	+11,353	New	+$2.1M	0.01%	282

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

TCW Group's CRL Position: Q2 2026 in Review

TCW Group increased its Charles River Laboratories (CRL) stake by 17% in Q2 2026, buying an estimated $334K and bringing the position to 13,230 shares worth $3M. The position accounts for 0.02% of the portfolio, ranked #253.

TCW Group first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

TCW Group held 13,230 shares of Charles River Laboratories worth $3M as of Q2 2026.
TCW Group bought 1,877 Charles River Laboratories shares in Q2 2026, an estimated $334K.
Charles River Laboratories made up 0.02% of TCW Group's portfolio in Q2 2026, its #253 holding.
TCW Group first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on TCW Group's 13F filing for Q2 2026, filed 3 Aug 2026.